685
Views
1
CrossRef citations to date
0
Altmetric
Research Article

Inhibition of the lethality of Shiga-like toxin-1 by functional gold nanoparticles

, &
Pages 841-851 | Received 21 Oct 2017, Accepted 04 Feb 2018, Published online: 15 Feb 2018

References

  • Motarjemi Y, Kaferstein F, Moy G, et al. Contaminated weaning food: a major risk factor for diarrhea and associated malnutrition. Bull World Health Organ. 1993;71:79–92.
  • Read SC, Gyles CL, Clarke RC, et al. Prevalence of verocytotoxigenic Escherichia coli in ground beef, pork, and chicken in southwestern Ontario. Epidemiol Infect. 1990;105:11–20.
  • Slutsker L, Ries AA, Maloney K, et al. A nationwide case-control study of Escherichia coli O157:H7 infection in the United States. J Infect Dis. 1998;177:962–966.
  • Flores FX, Jabs K, Thorne GM, et al. Immune response to Escherichia coli O157:H7 in hemolytic uremic syndrome following salmonellosis. Pediatr Nephrol. 1997;11:488–490.
  • Boyce TG, Swerdlow DL, Griffin PM. Current concepts: Escherichia coli O157:H7 and the hemolytic-uremic syndrome. N Engl J Med. 1995;333:364–368.
  • Kitova EN, Kitov PI, Bundle DR, et al. The observation of multivalent complexes of Shiga-like toxin with globotriaoside and the determination of their stoichiometry by nanoelectrospray Fourier-transform ion cyclotron resonance mass spectrometry. Glycobiology. 2001;11:605–611.
  • Franz E, Klerks MM, De Vos OJ, et al. Prevalence of Shiga toxin-producing Escherichia coli stx1, stx2, eaeA, and rfbE genes and survival of E. coli O157:H7 in manure from organic and low-input conventional dairy farms. Appl Environ Microbiol. 2007;73:2180–2190.
  • Rodrigue DC, Mast EE, Greene KD, et al. A university outbreak of Escherichia coli O157: H7 infections associated with roast beef and an unusually benign clinical course. J Infect Dis. 1995;172:1122–1125.
  • Orden JA, Cid D, Ruiz‐Santa‐Quiteria JA, et al. Verotoxin‐producing Escherichia coli (VTEC), enteropathogenic E. coli (EPEC) and necrotoxigenic E. coli (NTEC) isolated from healthy cattle in Spain. J Appl Microbiol. 2002;93:29–35.
  • Wells JG, Shipman LD, Greene KD, et al. Isolation of Escherichia coli serotype O157: H7 and other Shiga-like- toxin-producing E. coli from dairy cattle. J Clin Microbiol. 1991;29:985–989.
  • Lahti E, Eklund M, Ruutu P, et al. Use of phenotyping and genotyping to verify transmission of Escherichia coli O157:H7 from dairy farms. Eur J Clin Microbiol Infect Dis. 2002;21:189–195.
  • O’Brien AD, Newland JW, Miller SF, et al. Shiga-like toxin-converting phages from Escherichia coli strains that cause hemorrhagic colitis or infantile diarrhea. Science. 1984;226:694–696.
  • Jackson MP, Neill RJ, O’Brien AD, et al. Nucleotide sequence analysis and comparison of the structural genes for Shiga-like toxin I and Shiga-like toxin II encoded by bacteriophages from Escherichia coli 933. FEMS Microbiol Lett. 1987;44:109–114.
  • Donohue-Rolfe A, Acheson DW, Kane AV, et al. Purification of Shiga toxin and Shiga-like toxins I and II by receptor analog affinity chromatography with immobilized P1 glycoprotein and production of cross-reactive monoclonal antibodies. Infect Immun. 1989;57:3888–3893.
  • Fraser ME, Fujinaga M, Cherney MM, et al. Structure of Shiga toxin type 2 (Stx2) from Escherichia coli O157:H7. J Biol Chem. 2004;279:27511–27517.
  • Lingwood CA, Law H, Richardson S, et al. Glycolipid binding of purified and recombinant Escherichia coli produced verotoxin in vitro. J Biol Chem. 1987;262:8834–8839.
  • Cherian RM, Gaunitz S, Nilsson A, et al. Shiga-like toxin binds with high avidity to multivalent O-linked blood group P1 determinants on mucin-type fusion proteins. Glycobiology. 2014;24:26–38.
  • Ching JC, Jones NL, Ceponis PJ, et al. Escherichia coli Shiga-like toxins induce apoptosis and cleavage of poly(ADP-ribose) polymerase via in vitro activation of caspases. Infect Immun. 2002;70:4669–4677.
  • Tesh VL, Samoel JE, Perera LP, et al. Evaluation of the role of Shiga and Shiga-like toxins in mediating direct damage to human vascular endothelial cells. J Infect Dis. 1991;164:344–352.
  • Karmali MA. Prospects for preventing serious systemic toxemic complications of Shiga toxin-producing Escherichia coli infections using Shiga toxin receptor analogues. J Infect Dis. 2004;189:355–359.
  • Walterspiel JN, Morrow AL, Cleary TG, et al. Effect of subinhibitory concentrations of antibiotics on extracellular Shiga-like toxin I. Infection. 1992; 20:25–29.
  • Donta ST, Tomicic TK, Donohue-Rolfe A. Inhibition of Shiga-like toxins by brefeldin A. J Infect Dis. 1995;171:721–724.
  • Dong J, Zhang Y, Chen Y, et al. Baicalin inhibits the lethality of Shiga-like toxin 2 in mice. Antimicrob Agents Chemother. 2015;59:7054–7060.
  • Miyashita S, Matsuura Y, Miyamoto D, et al. Development of recombinant B subunit of Shiga-like toxin 1 as a probe to detect carbohydrate ligands in immunochemical and flow cytometric application. Glycoconj J. 1999;16:697–705.
  • Kitov PI, Sadowska JM, Mulvey G, et al. Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands. Nature. 2000;403:669–672.
  • Jacewicz MS, Acheson DW, Mobassaleh M, et al. Maturational regulation of globotriaosylceramide, the Shiga-like toxin 1 receptor, in cultured human gut epithelial cells. J Clin Invest. 1995;96:1328–1335.
  • Kuo FY, Chang BY, Wu CY, et al. Magnetic nanoparticle-based platform for characterization of Shiga-like Toxin 1 from complex samples. Anal Chem. 2015;87:10513–10520.
  • Lin PC, Yu CC, Wu HT, et al. A chemically functionalized magnetic nanoplatform for rapid and specific biomolecular recognition and separation. Biomacromolecules. 2012;14:160–168.
  • Wang B, Boons G-J. Carbohydrate recognition: biological problems, methods, and applications. New Jersey: John Wiley & Sons; 2011.
  • Suzuki N, Khoo KH, Chen HC, et al. Isolation and characterization of major glycoproteins of pigeon egg white ubiquitous presence of unique N-glycans containing Galα(1–4)Gal. J Biol Chem. 2001;276:23221–23229.
  • Bock K, Breimer ME, Brignole A, et al. Specificity of binding of a strain of uropathogenic Escherichia coli to Gal alpha 1—4 Gal-containing glycosphingolipids. J Biol Chem. 1985;260:8545–8551.
  • Takahashi N, Khoo KH, Suzuki N, et al. N-glycan structures from the major glycoproteins of pigeon egg white predominance of terminal Galα (1) Gal. J Biol Chem. 2001;276:23230–23239.
  • Sequence of pigeon ovalbumin information [Internet]. [cited 2018 Feb 12]. Available from: http://www.uniprot.org/uniprot/H9CJM6
  • Huang WC, Tsai PJ, Chen YC. Functional gold nanoparticles as photothermal agents for selective-killing of pathogenic bacteria. Nanomedicine. 2007;2:777–787.
  • Ho KC, Tsai PJ Lin YS, et al. Using biofunctionalized nanoparticles to probe pathogenic bacteria. Anal Chem. 2004;76:7162–7168.
  • Lin CC, Yeh YC, Yang CY, et al. Selective binding of mannose-encapsulated gold nanoparticles to type 1 pili in Escherichia coli. J Am Chem Soc. 2002;124:3508–3509.
  • Lai HZ, Chen WY, Wu CY, et al. Potent antibacterial nanoparticles for pathogenic bacteria. ACS Appl Mater Interfaces. 2015;7:2046–2054.
  • Das SK, Dickinson C, Lafir F, et al. Synthesis, characterization and catalytic activity of gold nanoparticles biosynthesized with Rhizopus oryzae protein extract. Green Chem. 2012;14:1322–1334.
  • Leifert A, Pan-Bartnek Y, Simon U, et al. Molecularly stabilised ultrasmall gold nanoparticles: synthesis, characterization and bioactivity. Nanoscale. 2013;2:6224–6242.
  • Li CH, Bai YL, Selvaprakash K, et al. Selective detection of Shiga-like toxin 1 from complex samples using pigeon ovalbumin functionalized gold nanoparticles as affinity probes. J Argic Food Chem. 2017;65:4359–4365.
  • Chen WY, Chen YC. Acceleration of microwave-assisted enzymatic digestion reactions by magnetite beads. Anal Chem. 2007;79:8061–8066.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.